Publications by authors named "Helen Feilden"

Claim this Profile
Q
Quality by digital design in action: a workflow for crystallisation and isolation.
Ian Houson, Humera Siddique, Magdalene W S Chong, Murray Robertson, Alice J Turner, Helen Feilden

Int J Pharm· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality by digital design to accelerate sustainable medicines development.
Chantal L Mustoe, Alice J Turner, Stephanie J Urwin, Ian Houson, Helen Feilden

Int J Pharm· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of potent, soluble and orally active TRPV1 antagonists. Structure-activity relationships of a series of isoxazoles.
Paul Ratcliffe, Lynn Abernethy, Nasrin Ansari, Ken Cameron, Tom Clarkson, Helen Feilden

Bioorg Med Chem Lett· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of potent, soluble, and orally active TRPV1 antagonists.
Paul Ratcliffe, John Maclean, Lynn Abernethy, Tom Clarkson, Maureen Dempster, Helen Feilden

Bioorg Med Chem Lett· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists.
Takao Kiyoi, Julia M Adam, John K Clark, Keneth Davies, Anna-Marie Easson, Helen Feilden

Bioorg Med Chem Lett· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-activity studies of a novel series of isoxazole-3-carboxamide derivatives as TRPV1 antagonists.
Ronald Palin, Lynn Abernethy, Nasrin Ansari, Kenneth Cameron, Tom Clarkson, Helen Feilden

Bioorg Med Chem Lett· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid access towards follow-up NOP receptor agonists using a knowledge based approach.
Ronald Palin, John K Clark, Louise Evans, Helen Feilden, Dan Fletcher

Bioorg Med Chem Lett· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and evaluation of N-3 substituted phenoxypropyl piperidine benzimidazol-2-one analogues as NOP receptor agonists with analgesic and sedative properties.
Ronald Palin, Anton Bom, John K Clark, Louise Evans, Helen Feilden

Bioorg Med Chem· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and SAR studies of 3-phenoxypropyl piperidine analogues as ORL1 (NOP) receptor agonists.
Ronald Palin, David R Barn, John K Clark, Jean E Cottney, Phillip M Cowley, Helen Feilden

Bioorg Med Chem Lett· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships.
Julia M Adam, D Jonathan Bennett, Anton Bom, John K Clark, Helen Feilden

J Med Chem· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host.
Anton Bom, Mark Bradley, Ken Cameron, John K Clark, Jan Van Egmond, Helen Feilden

Angew Chem Int Ed Engl· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis